(Q37898105)

25 August 2017

1 reference

title

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies (English)

1 reference

25 August 2017

Janet E Dancey

1

1 reference

PubMed ID

21732754

25 August 2017

Jose Monzon

series ordinal

2

1 reference

PubMed ID

21732754

25 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

7

1 reference

25 August 2017

827-839

1 reference

Targeted therapies in soft tissue sarcomas

25 August 2017

1 reference

Imatinib treatment for gastrointestinal stromal tumour (GIST).

21 January 2018

1 reference

mTOR signaling and drug development in cancer

21 January 2018

1 reference

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.

21 January 2018

1 reference

A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.

21 January 2018

1 reference

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

21 January 2018

1 reference

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas

21 January 2018

1 reference

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma

21 January 2018

1 reference

The pharmacology of mTOR inhibition

21 January 2018

1 reference

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

21 January 2018

1 reference

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.57

1 reference

25 August 2017

1 reference

PubMed ID

21732754